SI1368019T2 - Formulacija esmolola - Google Patents

Formulacija esmolola

Info

Publication number
SI1368019T2
SI1368019T2 SI200230444T SI200230444T SI1368019T2 SI 1368019 T2 SI1368019 T2 SI 1368019T2 SI 200230444 T SI200230444 T SI 200230444T SI 200230444 T SI200230444 T SI 200230444T SI 1368019 T2 SI1368019 T2 SI 1368019T2
Authority
SI
Slovenia
Prior art keywords
esmolol
hydrochloride
esmolol formulation
formulation
isopropylamino
Prior art date
Application number
SI200230444T
Other languages
English (en)
Other versions
SI1368019T1 (sl
Inventor
Jie Liu
Satish K Pejaver
George Owoo
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26688377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1368019(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/759,547 external-priority patent/US6310094B1/en
Application filed by Baxter Int filed Critical Baxter Int
Publication of SI1368019T1 publication Critical patent/SI1368019T1/sl
Publication of SI1368019T2 publication Critical patent/SI1368019T2/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
SI200230444T 2001-01-12 2002-01-02 Formulacija esmolola SI1368019T2 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/759,547 US6310094B1 (en) 2001-01-12 2001-01-12 Ready-to-use esmolol solution
US10/016,260 US6528540B2 (en) 2001-01-12 2001-10-30 Esmolol formulation
EP02736473A EP1368019B2 (en) 2001-01-12 2002-01-02 Esmolol formulation
PCT/US2002/000329 WO2002076446A1 (en) 2001-01-12 2002-01-02 Esmolol formulation

Publications (2)

Publication Number Publication Date
SI1368019T1 SI1368019T1 (sl) 2007-02-28
SI1368019T2 true SI1368019T2 (sl) 2010-10-29

Family

ID=26688377

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200230444T SI1368019T2 (sl) 2001-01-12 2002-01-02 Formulacija esmolola

Country Status (21)

Country Link
EP (1) EP1368019B2 (sl)
JP (1) JP2004519506A (sl)
CN (1) CN1298320C (sl)
AT (1) ATE341319T1 (sl)
AU (1) AU2002309475B2 (sl)
BR (1) BR0203517A (sl)
CA (1) CA2410446C (sl)
CZ (1) CZ304290B6 (sl)
DE (1) DE60215129T3 (sl)
DK (1) DK1368019T4 (sl)
ES (1) ES2272720T5 (sl)
HU (1) HUP0204520A3 (sl)
IL (1) IL151359A (sl)
MX (1) MXPA03006229A (sl)
PL (1) PL216192B1 (sl)
RU (1) RU2286774C2 (sl)
SI (1) SI1368019T2 (sl)
SK (1) SK288113B6 (sl)
TR (1) TR200202557T1 (sl)
TW (1) TWI277414B (sl)
WO (1) WO2002076446A1 (sl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310094B1 (en) * 2001-01-12 2001-10-30 Baxter International Inc. Ready-to-use esmolol solution
EP1417962A1 (de) 2002-11-06 2004-05-12 AOP Orphan Pharmaceuticals AG Verfahren zur Herstellung eines Arzneimittels enthaltend Esmolol
JP4959335B2 (ja) * 2003-10-08 2012-06-20 マリンクロッド エルエルシー メチルフェニデート溶液および関連する投与および製造方法
CN1303987C (zh) * 2004-11-19 2007-03-14 陈庆财 注射用盐酸艾司洛尔冻干粉针剂及其制备方法
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
AU2014203121B2 (en) * 2007-05-22 2016-04-21 Baxter Healthcare Sa Concentrate esmolol
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
DK2234614T3 (da) * 2007-12-21 2013-02-11 Aop Orphan Pharmaceuticals Ag Farmaceutisk sammensætning til parenteral administration af et ultrakort virkende beta-receptorblokerende middel
PT2480204E (pt) * 2009-09-22 2014-01-22 Vlife Sciences Technologies Pvt Ltd Formulação tópica para úlceras do pé diabético
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
US8686036B2 (en) 2011-01-27 2014-04-01 Baxter International Inc. Methods of controlling heart rate while minimizing and/or controlling hypotension
WO2012103305A1 (en) * 2011-01-27 2012-08-02 Baxter International Inc. Use of (s) - esmolol for controlling venous irritation associated with the treatment of a cardiac disorder
UA115333C2 (uk) 2012-05-10 2017-10-25 ЕйОуПі ОРФАН ФАРМАСЬЮТІКАЛС АГ Склад есмололу для парентерального введення
US8835505B1 (en) 2013-03-15 2014-09-16 Welgrace Research Group Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container
CN104473869A (zh) * 2014-11-20 2015-04-01 北京京科泰来科技有限公司 一种艾司洛尔脂肪乳及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857552A (en) * 1988-06-08 1989-08-15 E. I. Du Pont De Nemours And Co. Stable pharmaceutical composition
CN1074763C (zh) * 1997-11-13 2001-11-14 山东省医药工业研究所 艾司洛尔盐酸盐的制备方法

Also Published As

Publication number Publication date
DK1368019T4 (da) 2010-07-19
DE60215129T3 (de) 2010-09-09
PL357387A1 (en) 2004-07-26
DK1368019T3 (da) 2006-12-11
CA2410446C (en) 2008-08-26
SK288113B6 (sk) 2013-08-02
WO2002076446A1 (en) 2002-10-03
EP1368019A1 (en) 2003-12-10
AU2002309475B2 (en) 2006-08-03
CA2410446A1 (en) 2002-10-03
TWI277414B (en) 2007-04-01
RU2286774C2 (ru) 2006-11-10
CZ304290B6 (cs) 2014-02-19
CZ20023825A3 (cs) 2003-02-12
EP1368019B2 (en) 2010-06-02
IL151359A (en) 2009-09-01
EP1368019B1 (en) 2006-10-04
MXPA03006229A (es) 2004-05-24
SI1368019T1 (sl) 2007-02-28
CN1455669A (zh) 2003-11-12
CN1298320C (zh) 2007-02-07
PL216192B1 (pl) 2014-03-31
DE60215129T2 (de) 2007-02-15
ES2272720T5 (es) 2010-10-25
BR0203517A (pt) 2003-06-03
JP2004519506A (ja) 2004-07-02
IL151359A0 (en) 2003-04-10
SK12782002A3 (sk) 2003-11-04
HUP0204520A2 (en) 2003-05-28
HUP0204520A3 (en) 2004-12-28
ATE341319T1 (de) 2006-10-15
RU2002132189A (ru) 2004-03-27
DE60215129D1 (de) 2006-11-16
TR200202557T1 (tr) 2003-06-23
ES2272720T3 (es) 2007-05-01

Similar Documents

Publication Publication Date Title
IL151359A0 (en) Esmolol formulation
EP1738756A3 (en) Esmolol formulation
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
PL343771A1 (en) N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
JO2282B1 (en) Oxazole derivatives
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
YU75903A (sh) Tiohidantoini i njihovo korišćenje u lečenju dijabetisa
DE602004011966D1 (en) Heterocyclylverbindungen
NO20050018L (no) Lasofoxifentabletter og belegg
BR0308133A (pt) Forma polimórfica cristalina de cloridrato de irinotecan
GB0109122D0 (en) Novel compounds
MX344556B (es) Agonista de subtipo de receptor 5-ht1a.
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
SE0102440D0 (sv) New compound
CA2438509A1 (en) Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
EP1411956B8 (en) Use of oversulfated polysaccharides as inhibitors of hiv
PL365258A1 (en) Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions
SE0002354D0 (sv) New formulation